Psilocybin-assisted therapy for reducing alcohol intake in patients with alcohol use disorder: protocol for a randomised, double-blinded, placebo-controlled 12-week clinical trial (The QUANTUM Trip Trial)

INTRODUCTION: Alcohol use disorder is a difficult-to-treat psychiatric disorder and a major burden on public health. Existing treatment efficacy is moderate, and relapse rates are high. Preliminary findings suggest that psilocybin, a psychedelic compound, can safely and reliably occasion highly mean...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Mathias Ebbesen, Stenbæk, Dea Siggaard, Juul, Tobias Søgaard, Fisher, Patrick MacDonald, Ekstrøm, Claus Thorn, Knudsen, Gitte Moos, Fink-Jensen, Anders
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Mental Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577917/
https://www.ncbi.nlm.nih.gov/pubmed/36241352
http://dx.doi.org/10.1136/bmjopen-2022-066019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9577917/
https://www.ncbi.nlm.nih.gov/pubmed/36241352
http://dx.doi.org/10.1136/bmjopen-2022-066019

Ejemplares similares